Your session is about to expire
← Back to Search
Rivaroxaban + Aspirin for Blood Clot Prevention After Joint Surgery (EPCATIII Trial)
EPCATIII Trial Summary
This trial will test whether adding rivaroxaban to aspirin helps prevent venous thromboembolism better than aspirin alone in patients undergoing hip or knee replacement surgery.
EPCATIII Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.EPCATIII Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am younger than 18 years old.I have liver disease or another condition that prevents me from taking rivaroxaban.You have previously taken part in the EPCAT III study.I am not taking strong medication that affects drug processing in my body.I need long-term blood thinners due to a health condition or a clot after surgery.I am not pregnant, breastfeeding, and I use effective birth control.I take more than 100 mg of aspirin daily.I was diagnosed with COVID-19 in the last 3 months.I have received blood thinners after surgery.I have not had major surgery in the last 3 months.I am scheduled for elective hip or knee replacement surgery at a participating hospital.You are expected to live for less than 6 months.I need major surgery after joint replacement within 3 months.You are allergic to aspirin or currently have a stomach problem that makes it unsafe for you to take aspirin.Your platelet count is less than 100 x 10^9 per liter before surgery.Your kidneys do not filter waste from your blood very well.I have had a blood clot in my leg or lung before.I had a hip or leg fracture in the last 3 months, not due to surgery.My cancer has spread to other parts of my body.You have a history of serious bleeding that makes it unsafe for you to take blood thinning medication.I have had or will have surgery on both hips, both knees, or both at the same time.You are allergic to food dye.
- Group 1: TKA-study arm
- Group 2: TKA-control arm
- Group 3: THA-study arm
- Group 4: THA-control arm
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What conditions or symptoms might acetylsalicylic acid 81 mg help to alleviate?
"Acetylsalicylic acid 81 mg can be used to ameliorate pain, myocardial infarction, and catarrh."
What other treatments are similar to what is being trialed here?
"Acetylsalicylic acid 81 mg is being trialed in 230 active clinical trials across 64 countries and 1585 cities. The first trial began in 2002 and, after completing its Phase 3 drug approval stage, involved 413 patients. 706 trials have been conducted in the 18 years since the original study."
Are medical professionals currently looking for test subjects for this experiment?
"According to the data available on clinicaltrials.gov, this trial is currently seeking patients. The study was originally posted on February 4th 2021 and was most recently edited on July 27th 2022."
What are the risks of taking acetylsalicylic acid 81 mg?
"There is some evidence that acetylsalicylic acid 81 mg is effective, as well as data from multiple rounds of testing that support its safety. Consequently, our team has given it a score of 3."
Share this study with friends
Copy Link
Messenger